Mutual Relationship between Tau and Central Insulin Signalling: Consequences for AD and Tauopathies?
- PMID: 29439247
- DOI: 10.1159/000487641
Mutual Relationship between Tau and Central Insulin Signalling: Consequences for AD and Tauopathies?
Abstract
Alzheimer disease (AD) is a progressive neurodegenerative disorder mainly characterized by cognitive deficits and neuropathological changes such as Tau lesions and amyloid plaques, but also associated with non-cognitive symptomatology. Metabolic and neuroendocrine abnormalities, such as alterations in body weight, brain insulin impairments, and lower brain glucose metabolism, which often precede clinical diagnosis, have been extensively reported in AD patients. However, the origin of these symptoms and their relation to pathology and cognitive impairments remain misunderstood. Insulin is a hormone involved in the control of energy homeostasis both peripherally and centrally, and insulin-resistant state has been linked to increased risk of dementia. It is now well established that insulin resistance can exacerbate Tau lesions, mainly by disrupting the balance between Tau kinases and phosphatases. On the other hand, the emerging literature indicates that Tau protein can also modulate insulin signalling in the brain, thus creating a detrimental vicious circle. The following review will highlight our current understanding of the role of insulin in the brain and its relation to Tau protein in the context of AD and tauopathies. Considering that insulin signalling is prone to be pharmacologically targeted at multiple levels, it constitutes an appealing approach to improve both insulin brain sensitivity and mitigate brain pathology with expected positive outcome in terms of cognition.
Keywords: Alzheimer disease; Brain insulin signalling; Metabolic disorders; Tau; Tauopathy.
© 2018 S. Karger AG, Basel.
Similar articles
-
[Brain insulin signaling and Tau: impact for Alzheimer's disease and Tauopathies].Med Sci (Paris). 2018 Nov;34(11):929-935. doi: 10.1051/medsci/2018238. Epub 2018 Dec 10. Med Sci (Paris). 2018. PMID: 30526837 Review. French.
-
Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model.Neurobiol Dis. 2019 May;125:14-22. doi: 10.1016/j.nbd.2019.01.008. Epub 2019 Jan 19. Neurobiol Dis. 2019. PMID: 30665005
-
Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.Acta Neuropathol. 2015 Feb;129(2):221-37. doi: 10.1007/s00401-014-1373-0. Epub 2014 Dec 24. Acta Neuropathol. 2015. PMID: 25534024 Free PMC article.
-
Tau pathology in Alzheimer disease and other tauopathies.Biochim Biophys Acta. 2005 Jan 3;1739(2-3):198-210. doi: 10.1016/j.bbadis.2004.09.008. Biochim Biophys Acta. 2005. PMID: 15615638 Review.
-
The use of mouse models to study cell-to-cell transmission of pathological tau.Methods Cell Biol. 2017;141:287-305. doi: 10.1016/bs.mcb.2017.06.009. Epub 2017 Jul 14. Methods Cell Biol. 2017. PMID: 28882308 Free PMC article.
Cited by
-
Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis.Transl Neurodegener. 2018 Dec 24;7:34. doi: 10.1186/s40035-018-0139-3. eCollection 2018. Transl Neurodegener. 2018. PMID: 30603085 Free PMC article. Review.
-
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes.Alzheimers Res Ther. 2020 Apr 7;12(1):40. doi: 10.1186/s13195-020-00607-4. Alzheimers Res Ther. 2020. PMID: 32264944 Free PMC article.
-
Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators.Saudi J Biol Sci. 2020 Feb;27(2):736-750. doi: 10.1016/j.sjbs.2019.12.028. Epub 2019 Dec 26. Saudi J Biol Sci. 2020. PMID: 32210695 Free PMC article. Review.
-
Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer's Disease Treatment.Pharmaceuticals (Basel). 2021 Sep 1;14(9):890. doi: 10.3390/ph14090890. Pharmaceuticals (Basel). 2021. PMID: 34577590 Free PMC article. Review.
-
Long-term use of metformin and Alzheimer's disease: beneficial or detrimental effects.Inflammopharmacology. 2023 Jun;31(3):1107-1115. doi: 10.1007/s10787-023-01163-7. Epub 2023 Feb 28. Inflammopharmacology. 2023. PMID: 36849855 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical